These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32755155)

  • 1. The Negative Predictive Value of a PI-RADS Version 2 Score of 1 on Prostate MRI and the Factors Associated With a False-Negative MRI Study.
    Ma HY; Ahmed FS; Luk L; Martina LAP; Wenske S; Shaish H
    AJR Am J Roentgenol; 2020 Sep; 215(3):667-672. PubMed ID: 32755155
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of Prostate Imaging Reporting and Data System versions 1 and 2 for the Detection of Peripheral Zone Gleason Score 3 + 4 = 7 Cancers.
    Krishna S; McInnes M; Lim C; Lim R; Hakim SW; Flood TA; Schieda N
    AJR Am J Roentgenol; 2017 Dec; 209(6):W365-W373. PubMed ID: 28981356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI-RADS Version 2: Detection of Clinically Significant Cancer in Patients With Biopsy Gleason Score 6 Prostate Cancer.
    Seo JW; Shin SJ; Taik Oh Y; Jung DC; Cho NH; Choi YD; Park SY
    AJR Am J Roentgenol; 2017 Jul; 209(1):W1-W9. PubMed ID: 28418690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
    Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
    Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of Dynamic Contrast-enhanced and Diffusion MRI to PI-RADS for Detecting Clinically Significant Prostate Cancer.
    Tavakoli AA; Hielscher T; Badura P; Görtz M; Kuder TA; Gnirs R; Schwab C; Hohenfellner M; Schlemmer HP; Bonekamp D
    Radiology; 2023 Jan; 306(1):186-199. PubMed ID: 35972360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
    Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
    Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI.
    Sheridan AD; Nath SK; Syed JS; Aneja S; Sprenkle PC; Weinreb JC; Spektor M
    AJR Am J Roentgenol; 2018 Feb; 210(2):347-357. PubMed ID: 29112469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the Prostate Imaging Reporting and Data System, Version 2, on MRI Diagnosis for Extracapsular Extension of Prostate Cancer.
    Matsuoka Y; Ishioka J; Tanaka H; Kimura T; Yoshida S; Saito K; Fujii Y; Kihara K
    AJR Am J Roentgenol; 2017 Aug; 209(2):W76-W84. PubMed ID: 28570124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can Apparent Diffusion Coefficient Values Assist PI-RADS Version 2 DWI Scoring? A Correlation Study Using the PI-RADSv2 and International Society of Urological Pathology Systems.
    Gaur S; Harmon S; Rosenblum L; Greer MD; Mehralivand S; Coskun M; Merino MJ; Wood BJ; Shih JH; Pinto PA; Choyke PL; Turkbey B
    AJR Am J Roentgenol; 2018 Jul; 211(1):W33-W41. PubMed ID: 29733695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI-RADS Versions 2 and 2.1: Interobserver Agreement and Diagnostic Performance in Peripheral and Transition Zone Lesions Among Six Radiologists.
    Bhayana R; O'Shea A; Anderson MA; Bradley WR; Gottumukkala RV; Mojtahed A; Pierce TT; Harisinghani M
    AJR Am J Roentgenol; 2021 Jul; 217(1):141-151. PubMed ID: 32903060
    [No Abstract]   [Full Text] [Related]  

  • 11. Interreader Agreement of Prostate Imaging Reporting and Data System Version 2 Using an In-Bore MRI-Guided Prostate Biopsy Cohort: A Single Institution's Initial Experience.
    Glazer DI; Mayo-Smith WW; Sainani NI; Sadow CA; Vangel MG; Tempany CM; Dunne RM
    AJR Am J Roentgenol; 2017 Sep; 209(3):W145-W151. PubMed ID: 28657843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lesion volume predicts prostate cancer risk and aggressiveness: validation of its value alone and matched with prostate imaging reporting and data system score.
    Martorana E; Pirola GM; Scialpi M; Micali S; Iseppi A; Bonetti LR; Kaleci S; Torricelli P; Bianchi G
    BJU Int; 2017 Jul; 120(1):92-103. PubMed ID: 27608292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of Prostate Imaging Reporting and Data System Version 2 (PI-RADS v2): Interobserver Agreement and Positive Predictive Value for Localization of Intermediate- and High-Grade Prostate Cancers on Multiparametric Magnetic Resonance Imaging.
    Chen F; Cen S; Palmer S
    Acad Radiol; 2017 Sep; 24(9):1101-1106. PubMed ID: 28546032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep Learning-Based T2-Weighted MR Image Quality Assessment and Its Impact on Prostate Cancer Detection Rates.
    Lin Y; Belue MJ; Yilmaz EC; Harmon SA; An J; Law YM; Hazen L; Garcia C; Merriman KM; Phelps TE; Lay NS; Toubaji A; Merino MJ; Wood BJ; Gurram S; Choyke PL; Pinto PA; Turkbey B
    J Magn Reson Imaging; 2024 Jun; 59(6):2215-2223. PubMed ID: 37811666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary?
    Felker ER; Raman SS; Margolis DJ; Lu DSK; Shaheen N; Natarajan S; Sharma D; Huang J; Dorey F; Marks LS
    AJR Am J Roentgenol; 2017 Dec; 209(6):1272-1277. PubMed ID: 28858541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.
    Brizmohun Appayya M; Sidhu HS; Dikaios N; Johnston EW; Simmons LA; Freeman A; Kirkham AP; Ahmed HU; Punwani S
    Br J Radiol; 2018 Feb; 91(1083):20170645. PubMed ID: 29189042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
    Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
    BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of PI-RADS classification in MRI-directed transrectal ultrasound guided prostate biopsy.
    NiMhurchu E; O'Kelly F; Murphy IG; Lavelle LP; Collins CD; Lennon G; Galvin D; Mulvin D; Quinlan D; McMahon CJ
    Clin Radiol; 2016 Apr; 71(4):375-80. PubMed ID: 26880299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of prostate cancer in PI-RADS version 2.1 T2-weighted transition zone 'nodule in nodule' and 'homogeneous mildly hypointense area between nodules' criteria: MRI-radical prostatectomy histopathological evaluation.
    Lim CS; Abreu-Gomez J; Flood TA; Carrion I; Dallaire FB; Schieda N
    Eur Radiol; 2021 Oct; 31(10):7792-7801. PubMed ID: 33782767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification of Cancer at Prostate MRI: Deep Learning versus Clinical PI-RADS Assessment.
    Schelb P; Kohl S; Radtke JP; Wiesenfarth M; Kickingereder P; Bickelhaupt S; Kuder TA; Stenzinger A; Hohenfellner M; Schlemmer HP; Maier-Hein KH; Bonekamp D
    Radiology; 2019 Dec; 293(3):607-617. PubMed ID: 31592731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.